Amide derivatives useful as inhibitors of the production of cytokines
CA 2338121 A1 · Owner: Astrazeneca Ab · Inventors: Brown, George Robert; Brown, Dearg Sutherland
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
The invention concerns amide derivatives of formula (I) wherein R3 is (1- 6C)alkyl or halogeno; Q1 is heteroaryl which is optionally substituted with 1 2, 3, or 4 substituents such as hydroxy halogeno, trifluoromethyl, (1-, 6C)alkyl (1-6C)alkoxy, hydroxy-(1-6C)alkyl, (1-6C)alkoxy-(1-6C)alkyl hydroxy-, (2-6C)alkoxy, amino-(2-6C)alkylamino <u>N</u>-(1-6C)alkyl-(1-6C)alkylamino-(2- 6C)alkylamino, aryl, heteroaryl and heterocyclyl; p is 0-2 and R2 is a substituent such as hydroxy and halogeno; q is 0-4; and Q2 includes optionally substituted aryl, cycloalkyl, heteroaryl and heterocyclyl; or pharmaceuticallyacceptable salts or in vivo-cleavable esters thereof; processes for their preparation, …
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed July 29, 1999. No grant is recorded for it in Canada; had it been granted, its 20-year term would have ended July 29, 2019.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by July 29, 2021.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.